Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One shot for two viruses: new combo vaccine trial shows promise

NCT ID NCT06864143

Vaccine Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new combination vaccine called mRNA-1083 that aims to protect against both flu and COVID-19 in a single shot. About 1,320 adults aged 18 to 64 took part. Researchers measured the immune response and checked for side effects to see if the combo vaccine works as well as separate vaccines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

1,320 people

The number who actually took part.

Started

Mar 2025

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Medically stable. * Participants who could become pregnant: negative pregnancy test and contraception for at least 28 days prior to Day 1 and for at least 90 days after the study intervention administration. * Have received ≥2 coronavirus disease 2019 (COVID-19) vaccines, with the last COVID-19 vaccine administered \>150 days prior to Day 1. Exclusion Criteria: * History of a diagnosis or condition that is clinically unstable or may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures. * Tested positive for influenza by local health authority-approved testing methods within 150 days prior to Day 1. * History of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 150 days prior to Day 1. * Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses (eg, infliximab), within 180 days prior to Day 1 or plans to do so during the study. * Received or plans to receive any vaccine authorized or approved by a local health agency within 28 days prior to Day 1 or plans to do so within 28 days post study injection. * Received a licensed seasonal influenza vaccine within 150 days prior to Day 1. * Received a licensed/authorized COVID-19 vaccine within 150 days prior to Day 1. * Received any investigational influenza vaccine, investigational COVID-19 vaccine, or investigational combination vaccine for influenza and COVID-19 within 12 months prior to Day 1. * Participated in a clinical study with investigational treatment within 90 days prior to Day 1 (Baseline). Other protocol-defined inclusion/exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza SARS-CoV-2

Contacts and locations

Locations

  • Artemis Research (Headlands)

    San Diego, California, 92103, United States

  • Clinical Research Atlanta (Headlands)

    Stockbridge, Georgia, 30281, United States

  • DM Clinical Research - Bellaire

    Houston, Texas, 77081, United States

  • DM Clinical Research - Boston

    Brookline, Massachusetts, 02446, United States

  • DM Clinical Research - Chicago

    Melrose Park, Illinois, 60160, United States

  • DM Clinical Research - Detroit

    Southfield, Michigan, 48076, United States

  • DM Clinical Research - Philadelphia

    Philadelphia, Pennsylvania, 19107, United States

  • DM Clinical Research - Tomball

    Tomball, Texas, 77375, United States

  • Headlands Research Scottsdale

    Scottsdale, Arizona, 85260, United States

  • Trial Management Associates, LLC

    Wilmington, North Carolina, 28403, United States

  • Trial Management Associates, LLC

    Myrtle Beach, South Carolina, 29572, United States

  • Velocity Clinical Research, Boise

    Meridian, Idaho, 83642, United States

  • Velocity Clinical Research, Cincinnati, Mt. Auburn

    Cincinnati, Ohio, 45219, United States

  • Velocity Clinical Research, Cincinnati, Springdale

    Cincinnati, Ohio, 45246, United States

  • Velocity Clinical Research, Lafayette

    Lafayette, Louisiana, 70809, United States

  • Velocity Clinical Research, Norfolk

    Norfolk, Nebraska, 68701, United States

  • Velocity Clinical Research, Rockville

    Rockville, Maryland, 20854, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.